Showing 1,421 - 1,440 results of 44,204 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ( 5 ((teer decrease) OR (mean decrease)) ))', query time: 1.24s Refine Results
  1. 1421
  2. 1422
  3. 1423

    Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

    Published 2025
    “…<p>The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic presents a major global health challenge. …”
  4. 1424
  5. 1425

    Transient neonatal olfactory deprivation causes a persistent decrease in the addition of CR+ PGCs. A by Yasuko Kato (122938)

    Published 2012
    “…. & reopening group was used as a control (control). The number of PGCs was quantified at P61. …”
  6. 1426
  7. 1427
  8. 1428

    Mean RRCPs in V1 and ventral category-selective areas (FFA and PPA). by Bin Wang (30851)

    Published 2013
    “…In general, similarly to the mean response amplitudes (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072728#pone-0072728-g004" target="_blank">Figure 4</a>), the RRCPs decreased as the eccentricity increased in V1 (p<0.001, A, B) and ventral category-selective areas (FFA and PPA, C, D). …”
  9. 1429
  10. 1430

    Substance P decreases PRL immunoreactivity in human epidermis. by Ewan A. Langan (405804)

    Published 2013
    “…<p>Epidermal PRL IR (black arrows) was examined in full-thickness human skin organ culture. (A) PRL IR in the control group was significantly greater than that in (B) Substance P treated skin. …”
  11. 1431
  12. 1432
  13. 1433
  14. 1434
  15. 1435
  16. 1436
  17. 1437
  18. 1438
  19. 1439
  20. 1440

    The effects of pretreatment with fingolimod-phosphate on BMECs in the presence of MS sera. by Hideaki Nishihara (545149)

    Published 2015
    “…Pretreatment with fingolimod-phosphate resulted in an increase in the claudin-5 protein levels (B) and TEER values (G) and a decrease in the VCAM-1 protein levels (F) in the BMECs, which were upregulated after exposure to the sera from all MS patients, including the RRMS-R, RRMS-S and SPMS patients, compared to that observed in the cells not pretreated with fingolimod-phosphate.…”